Partnership Opportunities

Want to Become the Go-To Provider to Aid Drug Developers in their Mission to Develop RNA Editing Therapeutics?

The RNA editing field is rapidly evolving with drug developers around the world racing to make best-in-class RNA editing therapeutics. To achieve this, leading experts are looking for service providers with capabilities in high throughput sequencing, synthesis, process development, purification, analytics, manufacturing, distributors and CROs to facilitate their R&D platforms.

This summit is your opportunity to communicate exciting progress to the decision-makers in the field, generate leads, and better understand what tools and services the market wants and needs. You can rely on our ability to advise and deliver the right opportunities for you.

If you offer relevant services and want to maximise your company’s exposure, contact us today to discuss your bespoke commercial package at the 5th RNA Editing Summit.

Partnership Benefits Include:

Benefit from Market Intelligence
Hear how and where pharmaceutical companies are looking for services and solutions to facilitate their R&D to match your solutions accordingly

Meet & Network in person with Industry Pioneers
With a room full of drug developers, meet prospective clients during speed networking breaks and informal networking receptions to fuel commercial opportunities

Position Yourself as an Industry Expert
With the growing landscape of RNA editing biotech companies, this meeting is a dedicated platform to put your independent expertise in front of the key decision-makers in the field

Raise Brand Awareness & Generate Commercial Collaborations
Benefit from pre and post-conference exposure to our key opinion leaders and make sure you connect with the hottest prospects

Who You Can Expect to Connect With:

Graph 2
Graph 1

Next Steps:

If you offer relevant services and would like to align your company within the RNA space, contact us to discuss a bespoke commercial package to promote your brand at the 5th RNA Editing Summit.